Cargando…

PIK3CA-Related Overgrowth Spectrum From Diagnosis to Targeted Therapy: A Case of CLOVES Syndrome Treated With Alpelisib

PIK3CA-related overgrowth spectrum (PROS) is an umbrella term referring to various clinical entities, which share the same pathogenetic mechanism. These conditions are caused by somatic gain-of-function mutations in PIK3CA, which encodes the 110-kD catalytic α subunit of PI3K (p110α). These PIK3CA m...

Descripción completa

Detalles Bibliográficos
Autores principales:	Pagliazzi, Angelica, Oranges, Teresa, Traficante, Giovanna, Trapani, Chiara, Facchini, Flavio, Martin, Alessandra, Semeraro, Alessandro, Perrone, Anna, Filippeschi, Cesare, Giglio, Sabrina
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Pediatrics
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8459713/ https://www.ncbi.nlm.nih.gov/pubmed/34568242 http://dx.doi.org/10.3389/fped.2021.732836

Ejemplares similares

Treatment of two infants with PIK3CA-related overgrowth spectrum by alpelisib
por: Morin, Gabriel, et al.
Publicado: (2022)

Successful Treatment of Hypoglycemia With Alpelisib in Pediatric Patients With PIK3CA-Related Overgrowth Spectrum
por: Nasomyont, Nat, et al.
Publicado: (2023)

Somatic non-cancerous PIK3CA-related overgrowth syndrome treated with alpelisib in North America
por: Garneau, Alexandre P., et al.
Publicado: (2021)

Response of Brain Metastases From PIK3CA-Mutant Breast Cancer to Alpelisib
por: Batalini, Felipe, et al.
Publicado: (2020)

Cancer-Associated PIK3CA Mutations in Overgrowth Disorders
por: Madsen, Ralitsa R., et al.
Publicado: (2018)

Alpelisib: A Novel Therapy for Patients With PIK3CA-Mutated Metastatic Breast Cancer
por: Wilhoit, Tori, et al.
Publicado: (2020)

Anticancer effects of alpelisib on PIK3CA-mutated canine mammary tumor cell lines
por: Yeom, Jiah, et al.
Publicado: (2023)

The Serum Immunoglobulin E Level: Is There a Relationship With the Clinical Course of the Gianotti-Crosti Syndrome?
por: Bassi, Andrea, et al.
Publicado: (2021)

Role of Alpelisib in the Treatment of PIK3CA-Mutated Breast Cancer: Patient Selection and Clinical Perspectives
por: Chang, Dwan-Ying, et al.
Publicado: (2021)

In vitro anticancer effects of alpelisib against PIK3CA-mutated canine hemangiosarcoma cell lines
por: Maeda, Marika, et al.
Publicado: (2022)

PIK3CA-related overgrowth with an uncommon phenotype: case report
por: Rotunno, Roberta, et al.
Publicado: (2022)

Clinical Delineation and Natural History of the PIK3CA-Related Overgrowth Spectrum**
por: Keppler-Noreuil, Kim M, et al.
Publicado: (2014)

PIK3CA-related overgrowth spectrum (PROS) presenting as isolated macrodactyly
por: Krishnamurthy, Kritika, et al.
Publicado: (2023)

Clinical Profile of Overgrowth Syndromes Consistent with PROS (PIK3CA-Related Overgrowth Syndromes)—A Case Series
por: Mathew, Lydia, et al.
Publicado: (2020)

Genetic counseling during COVID‐19 pandemic: Tuscany experience
por: Pagliazzi, Angelica, et al.
Publicado: (2020)

The way to precision medicine in gynecologic cancers: The first case report of an exceptional response to alpelisib in a PIK3CA-mutated endometrial cancer
por: Passarelli, Anna, et al.
Publicado: (2023)

A Mosaic PIK3CA Mutation in a Moroccan Female: Exploring the Diagnostic Challenges of PIK3CA-Related Overgrowth Spectrum
por: Ahakoud, Mohamed, et al.
Publicado: (2023)

Safety and efficacy of low-dose sirolimus in the PIK3CA-related overgrowth spectrum
por: Parker, Victoria E. R., et al.
Publicado: (2018)

PIK3CA-Related Overgrowth Syndrome (PROS) and Angiosarcoma: A Case Report
por: Weinstein, Brielle, et al.
Publicado: (2020)

PIK3CA-related overgrowth spectrum (PROS): a rare case report
por: Kalo, Cedra, et al.
Publicado: (2023)

A girl with CLOVES syndrome with a recurrent PIK3CA somatic mutation and pancreatic steatosis
por: Hanafusa, Hiroaki, et al.
Publicado: (2019)

A PIK3CA-mutant breast cancer metastatic patient-derived organoid approach to evaluate alpelisib treatment for multiple secondary lesions
por: Donzelli, Sara, et al.
Publicado: (2022)

Targeted treatment of severe vascular malformations harboring PIK3CA and TEK mutations with alpelisib is highly effective with limited toxicity
por: Sterba, Martin, et al.
Publicado: (2023)

Orofacial overgrowth with peripheral nerve enlargement and perineuriomatous pseudo-onion bulb proliferations is part of the PIK3CA-related overgrowth spectrum
por: Koutlas, Ioannis G., et al.
Publicado: (2021)

Orofacial overgrowth with peripheral nerve enlargement and perineuriomatous pseudo-onion bulb proliferations is part of the PIK3CA-related overgrowth spectrum
por: Koutlas, Ioannis G., et al.
Publicado: (2020)

Brain Abnormalities in PIK3CA-Related Overgrowth Spectrum: Physician, Patient, and Caregiver Experiences
por: Dexheimer, Joy, et al.
Publicado: (2022)

Non-hotspot PIK3CA mutations are more frequent in CLOVES than in common or combined lymphatic malformations
por: Brouillard, Pascal, et al.
Publicado: (2021)

A rare newly described overgrowth syndrome with vascular malformations-Cloves syndrome
por: Gopal, Balaji, et al.
Publicado: (2015)

Cloves Syndrome: A Rare Disorder of Overgrowth with Unusual Features – An Uncommon Phenotype?
por: Mahajan, Vikram K., et al.
Publicado: (2019)

Overgrowth Syndromes—Evaluation, Diagnosis, and Management
por: Manor, Joshua, et al.
Publicado: (2020)

Netherton Syndrome in Children: Management and Future Perspectives
por: Barbati, Federica, et al.
Publicado: (2021)

Mouse models of human PIK3CA-related brain overgrowth have acutely treatable epilepsy
por: Roy, Achira, et al.
Publicado: (2015)

Segmental epidermal nevus and mucosal neuromas associated with PIK3CA-related overgrowth spectrum disorder
por: Roth, Gretchen M., et al.
Publicado: (2018)

Letter to editor: Orofacial overgrowth with peripheral nerve enlargement and perineuriomatous pseudo-onion bulb proliferations is part of the PIK3CA-related overgrowth spectrum
por: Maldonado, Andrés A., et al.
Publicado: (2022)

Corrigendum: Overgrowth Syndromes—Evaluation, Diagnosis, and Management
por: Manor, Joshua, et al.
Publicado: (2020)

Biological treatments for pediatric Netherton syndrome
por: Pontone, Matteo, et al.
Publicado: (2022)

Alpelisib Efficacy in Hormone Receptor-Positive HER2-Negative PIK3CA-Mutant Advanced Breast Cancer Post-Everolimus Treatment
por: Raphael, Ari, et al.
Publicado: (2022)

A Rare Pathological Phenotype of Endometrioid Serous and Clear-Cell Ovarian Cancer with PIK3CA Mutations in Relation to The Excellent Response of Alpelisib
por: Bayram, Ertugrul, et al.
Publicado: (2023)

Early activating somatic PIK3CA mutations promote ectopic muscle development and upper limb overgrowth
por: Frisk, Sofia, et al.
Publicado: (2019)

Clinical experience with the AKT1 inhibitor miransertib in two children with PIK3CA-related overgrowth syndrome
por: Forde, Karina, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_caig29kal2ofr2vd9hcsm1qmni